1. In Vivo
  2. >>Archive

A Mechanistic Look at Diabetes Surgery

The notion of how Roux-en-Y achieves weight loss and reverses diabetes is changing. Francesco Rubino, MD, chief of gastrointestinal metabolic surgery at Cornell University's Weill Cornell Medical College is at the forefront of diabetes surgery. Rubino's diabetes surgery program aims to tease out the mechanisms by which gastric bypass reverses diabetes. Here, an interview with Dr. Rubino.

Francesco Rubino, MD, chief of metabolic surgery at Weill Cornell Medical College is leading the charge for diabetes surgery. He has published extensively on his theories concerning the effect on diabetes of bypassing the intestine, and, independently of weight loss, the potential mechanisms of action that lead to the reversal of type 2 diabetes. Rubino isn’t alone: bariatric surgeons, gastroenterologists and endocrinologists around the world are also studying the mechanisms of diabetes surgery, but Rubino attracted attention to the field in September 2008, when he spearheaded the First World Congress on Interventional Therapies for Type 2 Diabetes, sponsored by Weill Cornell Medical College and New York-Presbyterian Hospital. The first conference of its kind drew 1,000 people from all walks of diabetes care internationally, a measure of hot interest in diabetes intervention. IN VIVO spoke to Dr. Rubino about this emerging field.

Q: In Vivo: Please tell us about the diabetes surgery division at Weill Cornell-NY Presbyterian Hospital.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.